Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCENT 1: Mirikizumab Induction in Moderately to Severely Active Ulcerative Colitis
jRCT2080224155Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Mirikizumab IV induction with Placebo IV induction (2 arms). Started Nov 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224155.